José A. Bufill

4.2k total citations · 1 hit paper
20 papers, 1.2k citations indexed

About

José A. Bufill is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, José A. Bufill has authored 20 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 4 papers in Pathology and Forensic Medicine. Recurrent topics in José A. Bufill's work include Colorectal Cancer Treatments and Studies (8 papers), Lung Cancer Treatments and Mutations (6 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). José A. Bufill is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), Lung Cancer Treatments and Mutations (6 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). José A. Bufill collaborates with scholars based in United States, India and Russia. José A. Bufill's co-authors include Philip C. Mack, Jonathan W. Riess, Vincent A. Miller, Jeffrey S. Ross, Sai‐Hong Ignatius Ou, Garrett M. Frampton, John D. McPherson, Primo N. Lara, Nir Peled and Siraj M. Ali and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Internal Medicine and The American Journal of Medicine.

In The Last Decade

José A. Bufill

20 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Colorectal Cancer: Evidence for Distinct Genetic Categories Based on Proximal or Distal Tumor Location

1990 605 citations José A. Bufill Annals of Internal Medicine profile →

Peers

Countries citing papers authored by José A. Bufill

Since Specialization

Citations

This map shows the geographic impact of José A. Bufill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by José A. Bufill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites José A. Bufill more than expected).

Fields of papers citing papers by José A. Bufill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by José A. Bufill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by José A. Bufill. The network helps show where José A. Bufill may publish in the future.

Co-authorship network of co-authors of José A. Bufill

This figure shows the co-authorship network connecting the top 25 collaborators of José A. Bufill. A scholar is included among the top collaborators of José A. Bufill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with José A. Bufill. José A. Bufill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Type B Lactic Acidosis in a Patient with Mantle Cell Lymphoma 2023 ·Case Reports in Critical Care ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Shivani Patel, (unknown), (unknown), Anthony V. Thomas, (unknown), Mark Walsh, José A. Bufill	2
2	Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03) 2018 ·Breast Cancer Research and Treatment ·Lynne I. Wagner, Fengmin Zhao, Paul E. Goss, J. W. Chapman, Lois E. Shepherd, Timothy J. Whelan, Bassam Mattar, José A. Bufill, (unknown), (unknown), (unknown), (unknown), Daniel A. Nikcevich, George W. Sledge, David Cella	60
3	Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC 2018 ·Journal of Thoracic Oncology ·Jonathan W. Riess, David R. Gandara, Garrett M. Frampton, Russell W. Madison, Nir Peled, José A. Bufill, Grace K. Dy, Sai‐Hong Ignatius Ou, Philip J. Stephens, John D. McPherson, Primo N. Lara, Rebekah A. Burich, Jeffrey S. Ross, Vincent A. Miller, Siraj M. Ali, Philip C. Mack, Alexa B. Schrock	166
4	Lung sarcomatoid carcinoma (LSC) harbors targetable genomic alterations and high mutational burden as observed by comprehensive genomic profiling (CGP) 2016 ·Annals of Oncology ·Balázs Halmos, Garrett M. Frampton, James Suh, (unknown), Ranee Mehra, Stephen H. Buck, José A. Bufill, Nir Peled, Nagla Abdel Karim, Paul A. S. Fishkin, James A. Knost, S.-H.I. Ou, (unknown), (unknown), V. A. Miller, Siraj M. Ali, (unknown)	2
5	Comprehensive genomic profiling (CGP) of advanced cancers to identify MET exon 14 alterations that confer sensitivity to MET inhibitors. 2015 ·Journal of Clinical Oncology ·Garrett M. Frampton, Siraj M. Ali, Mark R. Rosenzweig, Jonathan W. Goldman, Carrie B. Lee, Jared Weiss, José A. Bufill, Ravi Salgia, Mohammad Jahanzeb, Kartik Konduri, Patrick M. Forde, Deborah Morosini, Jeffrey S. Ross, Sai‐Hong Ignatius Ou, Roman Yelensky, Vincent A. Miller, Philip J. Stephens	3
6	Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53 2012 ·Cancer Chemotherapy and Pharmacology ·E. Gabriela Chiorean, Sonal P. Sanghani, (unknown), Menggang Yu, Matthew Burns, Yan Tong, (unknown), (unknown), Bruce W. Robb, Julia K. Leblanc, (unknown), José A. Bufill, (unknown), Patrick J. Loehrer, Higinia R. Cárdenes	16
7	Phase I study of everolimus (RAD001) with irinotecan (Iri) and cetuximab (C) in second-line metastatic colorectal cancer (mCRC): Hoosier Oncology Group GI05-102—Final report. 2011 ·Journal of Clinical Oncology ·Safi Shahda, Ming Yu, Joel Picus, José A. Bufill, Wael A. Harb, Matthew Burns, Aaron John Spittler, Joseph M. Flynn, Yi Zeng, Gail H. Vance, Jingyi Wu, (unknown), P. J. Loehrer, E. Gabriela Chiorean	6
8	Phase I study of everolimus (RAD001) with irinotecan (Iri) and cetuximab (C) in second-line metastatic colorectal cancer: Hoosier Oncology Group GI05-102. 2011 ·Journal of Clinical Oncology ·(unknown), Ming Yu, Joel Picus, José A. Bufill, Wael A. Harb, Matthew Burns, Aaron John Spittler, Yi Zeng, (unknown), E. Gabriela Chiorean	1
9	Phase II Trial of Erlotinib and Docetaxel in Advanced and Refractory Hepatocellular and Biliary Cancers: Hoosier Oncology Group GI06-101 2011 ·The Oncologist ·E. Gabriela Chiorean, (unknown), Menggang Yu, Joel Picus, José A. Bufill, Yan Tong, (unknown), (unknown), (unknown), Patrick J. Loehrer	61
10	Randomized, Double-Blinded, Multicenter, Phase II Study of Pemetrexed, Carboplatin, and Bevacizumab with Enzastaurin or Placebo in Chemonaïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: Hoosier Oncology Group LUN06-116 2010 ·Journal of Thoracic Oncology ·(unknown), Wael A. Harb, Daniel S. Bradford, José A. Bufill, Sreenivasa Nattam, (unknown), William B. Fisher, Jane E. Latz, Xiaochun Li, Jingwei Wu, Nasser H. Hanna	23
11	Randomized, double blind, multicenter, phase II study of pemetrexed (PEM), carboplatin (CARBO), bevacizumab (BEV) with enzastaurin (ENZ) or placebo (PBO) in chemotherapy-naive patients with stage IIIB/IV non-small cell lung cancer (NSCLC): Hoosier Oncology Group (HOG) LUN06–116 2009 ·Journal of Clinical Oncology ·(unknown), Wael A. Harb, Daniel S. Bradford, José A. Bufill, Sreenivasa Nattam, (unknown), William B. Fisher, Jane E. Latz, Jingwei Wu, Nasser H. Hanna	8
12	A Phase II Study of Single Agent Gemcitabine in Relapsed or Refractory Follicular or Small Lymphocytic Non-Hodgkin Lymphomas 2005 ·American Journal of Clinical Oncology ·Kristen N. Ganjoo, Michael J. Robertson, William B. Fisher, Sin‐Ho Jung, J. McClean, (unknown), José A. Bufill, (unknown), Larry D. Cripe	6
13	Hereditary Desmoid Disease in a Family with a Germline <i>Alu I</i> Repeat Mutation of the APC Gene 1999 ·Human Heredity ·Kevin C. Halling, Carlo Lazzaro, Ronald Honchel, José A. Bufill, Steven M. Powell, Carola A.S. Arndt, Noralane M. Lindor	47
14	Age-related disease penetrance in a large medullary thyroid cancer family with a codon 609 RET gene mutation 1997 ·Molecular Diagnosis ·Kevin C. Halling, José A. Bufill, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	10
15	Phenotypic Expression of Disease in Families That Have Mutations in the 5′ Region of the Adenomatous Polyposis Coli Gene 1997 ·Annals of Internal Medicine ·Francis M. Giardiello, Jill D. Brensinger, Michael C. Luce, Gloria M. Petersen, Matthew C. Cayouette, Anne J. Krush, (unknown), Susan V. Booker, José A. Bufill, Stanley R. Hamilton	69
16	Intra-arterial Chemotherapy for Palliation of Fungating Breast Cancer 1994 ·American Journal of Clinical Oncology ·José A. Bufill, Rob Grace, (unknown)	10
17	Colorectal Cancer: Evidence for Distinct Genetic Categories Based on Proximal or Distal Tumor Location breakdown → 1990 ·Annals of Internal Medicine ·José A. Bufill	605
18	Sepsis associated with transfusion of red cells contaminated with Yersinia enterocolitica 1990 ·Transfusion ·(unknown), (unknown), (unknown), Matthew J. Arduino, (unknown), J. J. Farmer, (unknown), (unknown), (unknown), Alfred J. Grindon, Paul S. Johnson, Ronald G. Strauss, José A. Bufill, Paul S. Ritch, John R. H. Archer, Ofelia C. Tablan, William R. Jarvis	108
19	Amyl nitrite-induced hemolytic anemia 1989 ·The American Journal of Medicine ·James C. Brandes, José A. Bufill, Anthony V. Pisciotta	14
20	Pityrosporum Folliculitis after Bone Marrow Transplantation 1988 ·Annals of Internal Medicine ·José A. Bufill, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact